Centogene Adds New Transcriptomic Offering to Multiomic Diagnostic Portfolio
Centogene announced the expansion of MOx, the company’s multiomic diagnostic portfolio, now incorporating transcriptomic analysis.
Read MorePosted by Andy Lundin | Oct 10, 2023 | Sequencing Systems |
Centogene announced the expansion of MOx, the company’s multiomic diagnostic portfolio, now incorporating transcriptomic analysis.
Read MorePosted by Andy Lundin | Oct 5, 2023 | Cancer |
The FDA granted de novo marketing authorization for a test that can help detect genetic variants associated with a predisposition to cancers.
Read MorePosted by Chris Wolski | Oct 4, 2023 | Colorectal |
The ColoAlert test is designed as a complement to colonoscopies and is designed to help detect colorectal cancer early.
Read MorePosted by Andy Lundin | Oct 3, 2023 | Emerging & Zoonotic Diseases |
A pilot study demonstrated the importance of self-sampling in diagnosing asymptomatic or atypical cases of mpox.
Read MorePosted by Chris Wolski | Oct 3, 2023 | Molecular Diagnostics |
With antimicrobial resistance increasing, bioMérieux has committed significant resources to combat it. Labs are critical to this mission.
Read More